INCHEON, South Korea, March 13, 2015 -- Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization Application (MAA) for SB2, its Remicade (Infliximab) biosimilar candidate, has ...

At week 10, 88 percent and 72 percent of patients treated with 5 mg/kg and 3 mg/kg of REMICADE, respectively, achieved PASI 75 versus only 6 percent of patients receiving placebo (P < 0.001 for ...